<DOC>
	<DOCNO>NCT00019890</DOCNO>
	<brief_summary>RATIONALE : Vaccines may make body build immune response kill tumor cell . PURPOSE : Randomized phase II trial study effectiveness vaccine therapy treat patient high-risk stage III completely resect metastatic melanoma .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With High-Risk Stage III Completely Resected Metastatic Melanoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine immunologic activity CD34+ derive peripheral monocyte derive dendritic cell pulse MART-1 gp100 melanoma antigens patient high risk stage III completely resect metastatic melanoma . PROTOCOL OUTLINE : This randomize study . Patients receive dendritic cell derive either peripheral monocyte CD34+ cell . Dendritic cell pulse MART-1 gp100 immunodominant HLA-A201 peptide prior infusion , administer intralymphatically low extremity first 2 course . Beginning course 3 4 , dendritic cell administer subcutaneously anterior thigh . Dendritic cell administer extremity undergone lymph node dissection . Patients randomize follow treatment arm : Arm I : Patients undergo leukapheresis obtain peripheral monocyte . Patients receive dendritic cell derive peripheral mononuclear cell pulse MART-1 gp100 every 4 week 4 course . Arm II : Patients receive 5 daily subcutaneous injection filgrastim ( G-CSF ) follow leukapheresis day 5 and/or 6 . Patients receive dendritic cell derive CD34+ cell pulse MART-1 gp100 every 4 week 4 course . Patients follow 4 6 week . PROJECTED ACCRUAL : A maximum 28 patient ( 14 per treatment arm ) accrue study within 7 month .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics High risk stage III melanoma ( great 3 lymph node positive ) OR completely resect metastatic melanoma within 6 month surgery Disease free CT scan HLAA201 positive Prior/Concurrent Therapy Biologic therapy : At least 4 week since prior biologic therapy No prior MART1 gp100 peptide immunization No concurrent biologic therapy Chemotherapy : At least 4 week since prior chemotherapy No concurrent chemotherapy Endocrine therapy : At least 4 week since prior endocrine therapy No concurrent systemic steroid therapy Radiotherapy : At least 4 week since prior radiotherapy No concurrent radiotherapy Surgery : See Disease Characteristics No concurrent surgery Patient Characteristics Age : 16 Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm3 Platelet count least 90,000/mm3 No coagulation disorder Hepatic : Bilirubin great 1.6 mg/dL AST ALT less 3 time upper limit normal Renal : Creatinine great 2.0 mg/dL Cardiovascular : No major cardiac disease Pulmonary : No major pulmonary disease Other : Not pregnant nursing Fertile patient must use effective contraception No active systemic infection No autoimmune disorder HIV negative Hepatitis B surface antigen negative</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2001</verification_date>
	<keyword>adult solid tumor</keyword>
	<keyword>body system/site cancer</keyword>
	<keyword>cancer</keyword>
	<keyword>melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
	<keyword>skin tumor</keyword>
	<keyword>solid tumor</keyword>
	<keyword>stage III melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>stage , melanoma</keyword>
</DOC>